Research progress and nursing enlightenment of patient-reported outcome measures for cancer immuno-therapy

doi:10.3761/j.issn.0254-1769.2026.03.018

Abstract

Abstract:

With the widespread application of immunotherapy in cancer patients，immune-related adverse events have become a key focus of clinical attention. Accurately assessing these adverse reactions and their impact on patients’ health-related quality of life is an indispensable part of cancer immunotherapy. This article reviews the research progress of patient-reported outcomes，and summarizes the existing patient reported outcomes scale for cancer immunotherapy from two aspects of universality and specificity，with a focus on summarizing and comparing the content characteristics，limitations，and clinical application of existing tools. Building on this，it proposes future development directions to provide a reference for the optimal development，clinical translation，and nursing practice concerning these cancer immunotherapy-specific assessment tools.

Key words: Cancer, Immunotherapy, Patient-Reported Outcomes Measures, Review, Nursing Care

摘要：

随着免疫治疗在癌症患者中的广泛应用，免疫相关不良事件已成为临床关注的重点。准确评估这些不良反应及其对患者健康相关生活质量的影响，是癌症免疫治疗中不可忽视的一部分。该文对患者报告结局进行概述，并从普适性和特异性2个方面汇总现有的癌症免疫治疗患者报告结局量表，重点梳理并比较了现有工具的内容特点、不足及临床应用情况。在此基础上，提出未来发展方向，以便为癌症免疫治疗特异性评估工具的优化开发、临床转化应用及护理实践提供参考依据。

关键词: 癌症, 免疫治疗, 患者报告结局量表, 综述, 护理

ZHANG Defa, WANG Qian, JIN Yuqin, YAN Rong, MAO Huiqing, XU Ping, ZHANG Miaomiao. Research progress and nursing enlightenment of patient-reported outcome measures for cancer immuno-therapy[J]. Chinese Journal of Nursing, 2026, 61(3): 419-426.

张德发, 王倩, 金玉芹, 闫荣, 毛会清, 徐萍, 张淼淼. 癌症免疫治疗患者报告结局量表的研究进展及护理启示[J]. 中华护理杂志, 2026, 61(3): 419-426.

References 34

[1]	Ghemrawi R, Abuamer L, Kremesh S, et al. Revolutionizing can-cer treatment:recent advances in immunotherapy[J]. Biomedici-nes, 2024, 12(9):2158.
[2]	Neil VM, Lee SW. Advancing cancer treatment:a review of im-mune checkpoint inhibitors and combination strategies[J]. Can-cers, 2025, 17(9):1408.
[3]	Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:ASCO guideline update[J]. J Clin Oncol, 2021, 39(36):4073-4126. DOI URL
[4]	Zhang XM, Zhu LL, Zhang H, et al. CAR-T cell therapy in he-matological malignancies:current opportunities and challenges[J]. Front Immunol, 2022,13:927153.
[5]	Hsiehchen D, Watters MK, Lu R, et al. Variation in the asses-sment of immune-related adverse event occurrence,grade,and timing in patients receiving immune checkpoint inhibitors[J]. JAMA Netw Open, 2019, 2(9):e1911519. DOI URL
[6]	Liu YH, Zang XY, Wang JC, et al. Diagnosis and management of immune related adverse events(irAEs) in cancer immuno-therapy[J]. Biomed Pharmacother, 2019,120:109437.
[7]	Jennifer Wang S, Dougan SK, Dougan M. Immune mechanisms of toxicity from checkpoint inhibitors[J]. Trends Cancer, 2023, 9(7):543-553. DOI PMID
[8]	Lai-Kwon J, Thorner E, Rutherford C, et al. Integrating patient-reported outcomes into the care of people with advanced cancer-a practical guide[J]. Am Soc Clin Oncol Educ Book, 2024, 44(3):e438512. DOI URL
[9]	Department of Health and Human Services FDA Center for Drug Evaluation and Research US,Department of Health and Human Services FDA Center for Biologics Evaluation and Research US, Department of Health and Human Services FDA Center for Devices and Radiological Health US. Guidance for industry:patient-reported outcome measures:use in medical product development to support labeling claims:draft guidance[J]. Health Qual Life Outcomes, 2006,4:79.
[10]	Colomer-Lahiguera S, Bryant-Lukosius D, Rietkoetter S, et al. Patient-reported outcome instruments used in immune-check-point inhibitor clinical trials in oncology:a systematic review[J]. J Patient Rep Outcomes, 2020, 4(1):58. DOI PMID
[11]	Churruca K, Pomare C, Ellis LA, et al. Patient-reported outcome measures(PROMs):a review of generic and condition-specific measures and a discussion of trends and issues[J]. Health Ex-pect, 2021, 24(4):1015-1024.
[12]	吴傅蕾, 刘欢, 袁长蓉. 患者报告结局在肿瘤照护领域的应用现状及思考[J]. 解放军护理杂志, 2017, 34(3):47-50.
	Wu FL, Liu H, Yuan CR. Application status and thinking of patient report outcome in cancer care field[J]. Nurs J Chin PLA, 2017, 34(3):47-50.
[13]	孟祥敏, 王倩, 闫荣, 等. 结直肠癌患者报告结局评估工具及临床应用的研究进展[J]. 中华护理杂志, 2022, 57(9):1094-1099. DOI
	Meng XM, Wang Q, Yan R, et al. Research progress on assessment tools of patient-reported outcomes for colorectal cancer patients and the clinical application[J]. Chin J Nurs, 2022, 57(9):1094-1099. DOI
[14]	张柳媛, 孙尔维, 陈嘉盈, 等. 系统性红斑狼疮特异性患者报告结局评估工具的研究进展[J]. 护士进修杂志, 2025, 40(18):1961-1965.
	Zhang LY, Sun EW, Chen JY, et al. Research progress on spe-cific patient-reported outcomes assessment tools for patients with systemic lupus erythematosus[J]. J Nurses Train, 2025, 40(18):1961-1965.
[15]	Hansen AR, Ala-Leppilampi K, McKillop C, et al. Development of the Functional Assessment of Cancer Therapy-Immune Check-Point Modulator(FACT-ICM):a toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs[J]. Cancer, 2020, 126(7):1550-1558. DOI PMID
[16]	Meng XM, Shang MM, Wang Q, et al. Reliability and validity of the simplified Chinese version of the Functional Assessment of Cancer Therapy-Immune Check-Point Modulator[J]. Qual Life Res, 2023, 32(6):1581-1593. DOI
[17]	Bergerot PG, Bergerot CD, Silva JRG, et al. Exercising and im-muno-oncology treatment(ExIO):a Prospective pilot study for patients with solid tumors[J]. Support Care Cancer, 2024, 32(12):840. DOI PMID
[18]	Lu RQ, Yang ZH, Miao JX, et al. Latent profile analysis of self-management and its association with quality of life differen-ces in patients with cancer treated with immune checkpoint inhibitors[J]. Asia Pac J Oncol Nurs, 2025,12:100687.
[19]	Mendoza T, Sheshadri A, Altan M, et al. Evaluating the psy-chometric properties of the immunotherapy module of the MD Anderson symptom inventory[J]. J Immunother Cancer, 2020, 8(2):e000931. DOI URL
[20]	Wu XD, Xie JY, Lin XM, et al. Translation and validation of Chinese version of MDASI immunotherapy for early-phase trials module:a cross-sectional study[J]. BMC Nurs, 2023, 22(1):176. DOI
[21]	Mendoza TR, Hong DS, Peterson CB, et al. Patient-reported sym-ptom burden in patients with rare cancers receiving pembro-lizumab in a phase II clinical trial[J]. Sci Rep, 2022, 12(1):14367. DOI PMID
[22]	贺瑾, 冯丽娜, 李艳. 肿瘤免疫检查点抑制剂治疗症状评估量表的编制及信效度检验[J]. 中国实用护理杂志, 2023, 39(7):481-485.
	He J, Feng LN, Li Y, et al. Establishment and reliablity and validity test of the Symptom Assessment Scale for Patients Treated with Tumor Immune Checkpoint Inhibitors[J]. Chin J Pract Nurs, 2023, 39(7):481-485.
[23]	李宁, 张勇, 贾江坤. 恶性黑色素瘤患者接受免疫检查点抑制剂治疗相关症状群及影响因素[J]. 军事护理, 2024, 41(11):65-69.
	Li N, Zhang Y, Jia JK. Analysis of symptom clusters and influencing factors in malignant melanoma patients treated with immune checkpoint inhibitors[J]. Mil Nurs, 2024, 41(11):65-69.
[24]	严浩宇. 癌症免疫治疗患者症状自我报告量表的构建[D]. 苏州: 苏州大学, 2023.
	Yan HY. Construction of Symptom Self-Report Scale for cancer immunotherapy patients[D]. Suzhou: Soochow University, 2023.
[25]	Wang XS, Srour SA, Mendoza T, et al. Development and vali-dation of a patient-reported outcome measure to assess sym-ptom burden after chimeric antigen receptor T-cell therapy[J]. Br J Haematol, 2023, 201(4):738-746. DOI URL
[26]	MD Anderson Cancer Center. MD anderson symptom invento-ry-car module[EB/OL].[2025-09-09]. https://www.mdanderson.org/research/departments-labs-institutes/departments-divisions/sy-mptom-research/symptom-assessment-tools/md-anderson-symptom-inventory-car-module.html.
[27]	毛奕文. 行CAR-T疗法淋巴瘤患者电子化自我报告结局问卷的开发及应用[D]. 武汉: 华中科技大学, 2024.
	Mao YW. Development and application of electronic Self-Report Outcome Questionnaire for Lymphoma Patients under-going CAR-T therapy[D]. Wuhan: Huazhong University of Science and Technology, 2024.
[28]	彭娜娜, 张晓菊, 陈凤珍, 等. 肺癌免疫治疗PRO-CTCAE子集的构建[J]. 护士进修杂志, 2023, 38(19):1729-1734.
	Peng NN, Zhang XJ, Chen FZ, et al. Development of a PRO-CTCAE-based subset for patients with lung cancer receiving immunotherapy[J]. J Nurses Train, 2023, 38(19):1729-1734.
[29]	彭娜娜, 陆箴琦, 王佳蕾, 等. 肺癌免疫治疗患者疲乏相关症状群变化轨迹及其影响因素[J]. 肿瘤, 2024, 44(7):693-707.
	Peng NN, Lu ZQ, Wang JL, et al. The trajectory of fatigue-related symptom clusters and influencing factors in patients with lung cancer receiving immunotherapy[J]. Tumor, 2024, 44(7):693-707.
[30]	Fan TT, Zhu SY, Wang H, et al. Development and validation of the Self-Report Symptom Inventory of Immune-Related Ad-verse Events in Patients with Lung Cancer[J]. Asia Pac J Oncol Nurs, 2024, 11(12):100603. DOI URL
[31]	伍泳欣, 刘晓华, 吴莹嘉, 等. 非小细胞肺癌免疫检查点抑制剂治疗病人症状评估量表的构建[J]. 护理研究, 2023, 37(5):826-832.
	Wu YX, Liu XH, Wu YJ, et al. Construction of Symptom Asse-ssment Scale for patients with non- small cell lung cancer treated with immune checkpoint inhibitors[J]. Chin Nurs Res, 2023, 37(5):826-832.
[32]	尚子妺, 吴静, 周洁. 乳腺癌患者睡眠及相关症状的轨迹研究[J]. 中华护理杂志, 2019, 54(10):1456-1462. DOI
	Shang ZM, Wu J, Zhou J. A trajectory study of sleep and related symptoms in breast cancer patients based on ecolo-gical momentary assessment[J]. Chin J Nurs, 2019, 54(10):1456-1462.
[33]	王晴, 黄晓婷, 唐四元, 等. 即时适配干预在护理领域中的应用进展[J]. 中华护理杂志, 2024, 59(4):490-495. DOI
	Wang Q, Huang XT, Tang SY, et al. The application progress of just-in-time adaptive intervention in nursing[J]. Chin J Nurs, 2024, 59(4):490-495. DOI
[34]	刘瑾, 白蕊, 张佩英, 等. 2种量表用于慢性伤口患者生活质量测评的对比研究[J]. 中华护理杂志, 2023, 58(5):558-564. DOI
	Liu J, Bai R, Zhang PY, et al. Comparison of 2 questionnaires in evaluating the quality of life of patients with chronic wounds[J]. Chin J Nurs, 2023, 58(5):558-564. DOI